Northern Trust Company of Connecticut’s Myriad Genetics MYGN Stock Holding History

Northern Trust Company of Connecticut’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$2.07M	Sell	98,667 -65,425	-40%	-$1.65M	0.01%	1066
2013 Q3	$3.86M	Buy	164,092 +6,100	+4%	+$173K	0.02%	786
2013 Q2	$4.25M	Buy	+157,992	New	+$4.58M	0.03%	723

Other funds holding MYGN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 16.21% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

LCG

Luxor Capital Group New York $1.43B AUM 30.88% 1-Year Est. Return

MCM

Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.62% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Northern Trust Company of Connecticut's MYGN Position: Q4 2013 in Review

Northern Trust Company of Connecticut reduced its Myriad Genetics (MYGN) stake by 40% in Q4 2013, selling an estimated $1.65M and leaving 98,667 shares worth $2.07M. The position accounts for 0.01% of the portfolio, ranked #1066.

Northern Trust Company of Connecticut first reported a position in MYGN in Q2 2013 and has held it in 3 quarters since. The position peaked at $4.25M in Q2 2013. 271 funds tracked by Wall St. Rank hold MYGN as of Q4 2013.

Northern Trust Company of Connecticut held 98,667 shares of Myriad Genetics worth $2.07M as of Q4 2013.
Northern Trust Company of Connecticut sold 65,425 Myriad Genetics shares in Q4 2013, an estimated $1.65M.
Myriad Genetics made up 0.01% of Northern Trust Company of Connecticut's portfolio in Q4 2013, its #1066 holding.
Northern Trust Company of Connecticut first reported a position in Myriad Genetics in Q2 2013 and has held it in 3 quarters since.
Northern Trust Company of Connecticut's Myriad Genetics position peaked at $4.25M in Q2 2013.
271 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2013.

Based on Northern Trust Company of Connecticut's 13F filing for Q4 2013, filed 12 Feb 2014.